Skip to content

Philippines logo

Main menu
  • Home
  • Mission and Vision
  • Press releases
  • Contact Us

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Here for her health

We envision a better and healthier

every day for every woman

Organon (Philippines) Incorporated

Present in over 140 countries including the Philippines and with a portfolio of more than 60 medicines and products, Organon will help address a spectrum of conditions women face including reproductive health issues, heart disease, breast cancer, allergies, and asthma.

Our Commitment

At Organon, we believe in a better and healthier every day for every woman. And we
understand that women are foundational to a healthier world. As a new company,
we will begin by listening to women’s healthcare needs, big and small, enabling us
to develop treatments tailored to them – because we know there is so much more
we can do for women and their health.

The diversity of our business provides a sustainable engine of growth so we can
continue to invest in and advance new medicines and solutions for women that are
so urgently needed. We believe the journey to improve women’s health is critical to
achieving a healthier world. Our people – a global community thousands strong –
are united in our drive to better support the health of women within our company
and around the globe. Together, we work to deliver solutions for the healthcare
issues that matter most to her, today and every day.

Organon and Its Story

Organon became the name of a Netherlands-based company that was established in 1923,
and which grew as a European innovator and became known in the area of women’s health.
The company was a known innovator in women’s health. Organon was at the forefront of the
development of the first contraceptive pill. It also had several other innovations such as the first
single rod contraceptive implant and the first contraceptive ring.
Organon was acquired in 2007 by Schering-Plough and became part of Merck & Co., Inc. and MSD in
the 2009 merger. Now, the brand name is being rebirthed for a new company, but one with
important links to the past in terms of products and passion for women’s health.
Organon is a science-based global biopharmaceutical, healthcare company that develops and
delivers innovative health solutions through a portfolio of prescription therapies within women’s
health, biosimilars and established brands.

Our areas of focus

We build upon our strong foundation of more than 60 medicines and other products across arange of areas including reproductive health, heart disease, dermatology, allergies and asthma. And we bring these important therapies around the world, with an international footprint that serves people in more than 140 markets.

Women’s health

We know women need more choices when it comes to their healthcare. Through our portfolio of products specifically designed to address her needs, our goal is to create a better and healthier every day, for every woman.

Biosimilars

By providing access to biosimilars as an important treatment option, we aim to bring more choices to more patients who need them.

Established medicines

Our portfolio of established medicines has a long history and cover critical areas including cardiovascular, respiratory, dermatology and non-opioid pain management and more.

Previous
Next

We are Organon

Careers

Our people – a global community of thousands strong – are united in our drive to better support the health of women within our company and around the globe.

Join our team

Philippines logo
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept